Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.42 |
| ▸ | KDM5A | P29375 | 2/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.41 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.37 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | HTR2B | P41595 | 2/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.34 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9964442 | 0.90 | KDM5A (0.44) | SLC6A4KDM5AKDM4CKDM5BLRRK2 | |
| SCHEMBL12004723 | 0.84 | FFAR1 (0.42) | SLC6A4KDM5AKDM4CKDM5BLRRK2 | |
| SCHEMBL9966872 | 0.82 | KDM5A (0.47) | SLC6A4KDM5AKDM4CKDM5BFFAR1 | |
| SCHEMBL9966871 | 0.78 | KDM5A (0.55) | SLC6A4KDM5AKDM4CKDM5BFFAR1 | |
| SCHEMBL1746551 | 0.77 | KDM5A (0.41) | SLC6A4KDM5AKDM4CKDM5BFFAR1 | |
| SCHEMBL1745475 | 0.74 | FFAR1 (0.50) | SLC6A4KDM5AKDM4CKDM5BFFAR1 | |
| SCHEMBL12019265 | 0.73 | FFAR1 (0.47) | SLC6A4KDM5AKDM4CKDM5BFFAR1 | |
| SCHEMBL1746743 | 0.71 | KDM5A (0.40) | SLC6A4KDM5AKDM4CKDM5BFFAR1 | |
| SCHEMBL1747113 | 0.70 | SLC6A4 (0.41) | SLC6A4KDM5AKDM4CKDM5BLRRK2 | |
| SCHEMBL22992655 | 0.70 | FFAR1 (0.56) | SLC6A4KDM5AKDM4CKDM5BFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476287-B2 | 3-hydroxy-5-arylisothiazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-07-02 | — | — | US | disclosed |
| US-8476287-B2 | 3-hydroxy-5-arylisothiazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-07-02 | — | — | US | disclosed |
| US-20120157459-A1 | NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157459-A1 | NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE | GPR119, GPR27, NR0B1 | SLC6A4 2310/4885KDM5A 3166/4885KDM4C 3758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.